Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit involves claims that Elevance and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Elevance securities during the Class Period have until July 11, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Performance and Market Reaction - On July 17, 2024, Elevance's CEO reported a shift in Medicaid membership mix leading to increased acuity, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [4]. - During the October 17, 2024, earnings call, the CEO disclosed that adjusted diluted earnings per share for the third quarter were $8.37, below expectations due to elevated medical costs in Medicaid, causing a stock price decline of $52.61 per share, or 10.6%, closing at $444.35 [5]. - The full-year outlook for adjusted diluted earnings per share was reduced from $37.20 to approximately $33, despite previous guidance just three months earlier [5].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for allegedly misleading investors regarding the company's Medicaid cost trends and financial guidance during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Group 1: Allegations and Misrepresentation - The lawsuit claims that Elevance's management assured investors that they were monitoring Medicaid cost trends and that premium rates were sufficient to manage risks associated with Medicaid patients [2]. - It is alleged that while management acknowledged rising Medicaid expenses, they misrepresented that these were adequately reflected in the company's financial guidance for 2024 [2]. - The complaint states that management claimed to have "visibility into 75% of our Medicaid rates and premiums for 2024," asserting that the majority were actuarially sound, which is now disputed [2]. Group 2: Impact of Disclosures - The truth about rising acuity and utilization among Medicaid members began to emerge on July 17, 2024, when Elevance indicated an expectation of increased utilization in the second half of the year [3]. - Following this disclosure, Elevance's stock price fell by $32.21 per share, a decline of 5.8%, from $553.14 on July 16, 2024, to $520.93 on July 17, 2024 [3]. Group 3: Investor Actions - Investors who acquired shares of Elevance during the Class Period are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on July 11, 2025 [4].

Core Insights - Proactive provides fast, accessible, and informative business and finance news content to a global investment audience [2] - The company specializes in medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, mining, oil and gas, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

President Trump took aim at Big Pharma on Monday by signing an executive order meant to slash Americans’ prescription drug prices by up to 90% — sparking a selloff in companies he labeled as “middlemen.” “What’s been happening is, we’ve been subsidizing other countries throughout the world,” Trump explained at a White House signing ceremony, calling the action one of his “most important orders.”“Some prescription drug and pharmaceutical prices will be reduced almost immediately by 50 to 80 to 90%,” he added ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of UnitedHealth Group Incorporated (“UnitedHealth” or the “Company”) (NYSE: UNH) between December 3, 2024 and April 16, 2025, inclusive. For more information, submit a form at UnitedHealth Group Incorporated Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pal ...

SelectQuote (SLQT) Q3 2025 Earnings Call May 12, 2025 08:30 AM ET Company Participants Matthew Gunter - Chief Communication Officer & Investor RelationsTimothy Danker - Chief Executive OfficeRyan Clement - Chief Financial OfficerRobert Grant - PresidentMichael Murray - Equity Research Associate Conference Call Participants George Sutton - Partner & Senior Research AnalystPatrick McCann - Equity Research Analyst Operator Welcome to SelectQuote's Third Quarter Earnings Conference Call. All lines have been pla ...

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Humana Inc.  (“Humana” or the “Company”) (NYSE: HUM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Humana and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 1, 2025, the U.S. ...

NeueHealth First Quarter 2025 - Earnings Presentation Privileged & Confidential | © 2024 May 8, 2025 Disclaimer Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, as well as statements regardin ...

Core Viewpoint - Buying quality dividend stocks near multiyear lows can be advantageous for long-term investors, especially if the dividend remains intact as the stock price declines [1] Group 1: PepsiCo - PepsiCo has seen a 25% decline in value over the past 12 months, with first-quarter sales down approximately 2% [4] - Despite challenges, PepsiCo generated over 1% organic growth in the first quarter, and the decline in sales was significantly impacted by foreign exchange [5] - The company produced $7.3 billion in free cash flow over the last 12 months, matching its dividend payments, indicating that the dividend payout is not in imminent danger [6] Group 2: UnitedHealth Group - UnitedHealth Group is trading near a four-year low due to rising costs affecting its bottom line [7] - The company experienced a 4% year-over-year increase in adjusted earnings per share in the first quarter, despite challenges in its Medicare Advantage business [8] - With a modest payout ratio of 35%, UnitedHealth is not at serious risk of cutting its dividend, and it trades at a P/E multiple of 17, below its five-year average of nearly 20 [9] Group 3: United Parcel Service (UPS) - UPS is trading near its 52-week low, with revenue for the first quarter totaling $21.5 billion, slightly down from $21.7 billion in the previous year [10][11] - The company plans to cut 20,000 jobs and reduce deliveries involving Amazon to improve margins amid economic challenges [11] - UPS's diluted earnings per share were $1.40, below its quarterly dividend of $1.64, but the company has a plan to improve profitability, making it a potential contrarian buy [12][13]

Clover Health Investments, Corp. (CLOV) reported breakeven earnings for the first-quarter 2025, narrower than the year-ago period’s loss of 5 cents. The bottom line surpassed the Zacks Consensus Estimate of a loss of 7 cents. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Adjusted earnings per share (EPS) from continuing operations were approximately 5 cents compared with EPS of a cent in the year-ago period.CLOV’s Revenues in DetailClover Health registered revenues of $462.3 milli ...